Photochemical decontamination treatment of whole blood or blood components

• US 4,748,120 A
• Filed: 10/20/1986
• Issued: 05/31/1988
• Est. Priority Date: 05/02/1983
• Status: Expired due to Term

• Current Assignee: Miles, Inc. (Bayer AG)
• Original Assignee: Diamond Scientific Company
• Inventors: Wiesehahn, Gary P.
• Primary Examiner(s): Wiseman, Thomas G.
• Assistant Examiner(s): Teskin, Robin Lyn
• Application Number:
  US06/928,841
• Time in Patent Office: 589 Days
• Field of Search: 435/172.1, 435/173, 435/183, 435/188, 435/236, 435/238, 435/269, 435/800, 435/814, 424/89, 424/90, 424/101, 424/85, 514/2, 530/350, 530/363, 530/380-388, 530/412-414, 530/427
• US Class Current: 435/173.3
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61M 1/3681 by irradiation
• CPC Class Codes: A61M 1/3683 using photoactive agents
• CPC Class Codes: Y10S 530/829 Blood

Abstract

Biological compositions are freed of functional polynucleotides by treatment of the biological composition with psoralen derivatives under irradiation conditions in which the proteins retain their original physiological activities and any polynucleotide present is rendered inactive.

Claims

1. A method for decontaminating blood components suspected of containing viruses, said blood components being selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins, without substantial impairment of the physiological activities of the treated blood components, said method comprising:

(a) adding to a blood component selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins at least one psoralen compound in an amount sufficient to inactivate substantially all contaminating viruses prevent; and

thereafter

(b) irradiating said psoralen treated blood component with long wavelength ultraviolet light under operating conditions which maintain the concentrations of reactive oxygen species at levels which do not substantially impair the physiological activity of the treated blood component, and wherein said irradiation is conducted for a time sufficient to inactivate substantially all contaminating viruses present.

2. A method according to claim 1 wherein the conditions which maintain the concentration of reactive oxygen species at levels which do not substantially impair the physiological activity of the treated blood component comprise the addition of an oxygen scavenger.

3. A method according to claim 2 further comprising selectively removing any unreacted psoralen(s) or photobreakdown products thereof by ultrafiltration of dialysis.

4. A method according to claim 1, wherein at least two psoralens are present.

5. A method according to claim 1, wherein said component is immunoglobin.

6. A method according to claim 1, wherein said blood component is red cells.

7. A method according to claim 1, wherein said blood component is a clotting factor.

8. A method according to claim 1, wherein said blood component is platelets.

9. A method according to claim 1, wherein said blood component is plasma.

10. A method according to claim 1, wherein said psoralen has at least one substituent which is alkyl of from 1 to 3 carbon atoms, alkoxy of from 1 to 3 carbon atoms, or substituted aklyl of from 1 to 6 carbon atoms having 1 to 2 heteroatoms which are oxy or amino.

11. A method according to claim 1, wherein said psoralen has at least one substituent which is alkoxy of from 1 to 3 carbon atoms.

12. A method according to claim 11, wherein said psoralen is 5-methoxypsoralen (5-MOP), 8-methoxypsoralen (8-MOP) or 4'"'"'-methoxymethyl-4,5'"'"',8-trimethylpsoralen.

13. A method according to claim 1, wherein said psoralen has at least one substituent which is alkyl of from 1 to 3 carbon atoms.

14. A method according to claim 13, wherein said psoralen is 4,5'"'"',8-trimethylpsoralen (TMP), 4-methylpsoralen, 4,4'"'"'-dimethylpsoralen, 4,5'"'"'-dimethylpsoralen or 4'"'"',8-dimethylpsoralen.

15. A method according to claim 1, wherein said psoralen has at least one substituent which is alkyl of from 1 to 6 carbon atoms having from 1 to 2 heteroatoms which are oxy or amino.

16. A method according to claim 15, wherein said psoralen is 4'"'"'-hydroxymethyl-4,5'"'"',8-trimethylpsoralen (HMT) or 4'"'"'-aminomethyl-4,5'"'"',8-trimethylpsoralen (AMT).

17. A method for decontaminating blood components suspected of containing viruses, said blood components being selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins, without substantial impairment of the physiological activity of the treated blood components, said method comprising:

(a) adding to a blood component selected from the group consisting of red blood cells, platelets, blood clotting factors, plasma and immunoglobulins at least one psoralen compound in a total psoralen concentration of at least 1 ug/ml and not more than 300 ug/ml; and

thereafter

(b) passing said psoralen treated blood component through a light beam with a wavelength in the range of 300 nm to 400 nm at an intensity of about 0.1 mw/cm² to 5 W/m² at a depth of at least 0.025 mm for a total radiation time of about 5 minutes to about 12 hours, wherein said irradiation is conducted under operating conditions which maintain the concentrations of reactive oxygen species at levels which do not substantially impair the physiological activ of the treated blood component.

18. A method according to claim 17 wherein the conditions which maintain the concentrations of reactive oxygen species at levels which do not substantially impair the physiological activity of the treated blood component comprise the addition of an oxygen scavenger.

19. A method according to claim 18 further comprising selectively removing any unreacted psoralen(s) or photobreakdown products thereof by ultrafiltration or dialysis.

20. A method according to claim 17, wherein at least two psoralen are present.

21. A method according to claim 17, wherein said blood component is red cells.

22. A method according to claim 17 wherein said blood commponent is platelets.

23. A method according to claim 17 wherein said blood component is plasma.

24. A method according to claim 17 wherein said blood component is a clotting factor.

25. A method according to claim 17 wherein said blood component is an immunoglobin.

26. A method according to claim 17, wherein said psoralen has at least one substituent which is alkyl of from 1 to 3 carbon atoms, alkoxy of from 1 to 3 carbon atoms, or substituted alkyl of from 1 to 6 carbon atoms having 1 to 2 heteroatoms which are oxy or amino.

27. A method according to claim 17, wherein said psoralen has at least one substituent which is alkoxy of from 1 to 3 carbon atoms.

28. A method according to claim 27, wherein said psoralen is 5-methoxypsoralen (5-MOP), 8-methoxypsoralen (8-MOP) or 4'"'"'-methoxymethyl-4,5'"'"',8-trimethylpsoralen.

29. A method according to claim 17, wherein said psoralen has at least one substituent which is alkyl of from 1 to 3 carbon atoms.

30. A method according to claim 29, wherein said psoralen is 4,5'"'"',8-trimethylpsoralen (TMP), 4-methylpsoralen, 4,4'"'"'-dimethylpsoralen, 4,5'"'"'-dimethylpsoralen or 4'"'"',8-dimethylpsoralen.

31. A method according to claim 17, wherein said psoralen has at least one substituent which is alkyl of from 1 to 6 carbon atoms having from 1 to 2 heteroatoms which are oxy or amino.

32. A method according to claim 31, wherein said psoralen is 4'"'"'-hydroxymethyl-4,5'"'"',8-trimethylpsoralen (HMT) or 4'"'"'-aminomethyl-4,5'"'"',8-trimethylpsoralen (AMT).